The City of Leeds Youth Wind Orchestra in concert black stood with their instruments in front of a large audience in the hall of Pudsey Civic Hall for the City of Leeds Youth Music Prom Concert 26.

🎶 A brilliant City of Leeds Youth Music Prom concert for schools yesterday! Huge thanks to the Leeds Youth Jazz Rock Orchestra, Roots Alive and City of Leeds Youth Wind Orchestra for amazing performances — and to all the schools who joined us! 👏✨
#YouthMusic #MusicEducation #Leeds #CLYM #Pudsey

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates  Climb Bio (Nasdaq: CLYM) reported Q4 and full-year 2025 results and clinical updates on March 5, 2026. The company ended 2025 with $160.7 million in cash and expects runway into 2028. Multiple budoprutug trials are underway, a subcutaneous dosing study completed, and several initial data readouts are expected across 2026.CLYM116 Phase 1 enrollment continues with initial healthy-volunteer data anticipated mid-2026; IND clearance obtained in China for a parallel SLE study.

#CLYM Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates 

www.stocktitan.net/news/CLYM/climb-bio-repo...

Most Searched, Monday December 15, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Dec 15th - #QUBT #KYTX #NVTS #JBLU #CLYM #RR #BEAT #BTBT #RADX #DNN #ARTV #BITF #MIST #PLUG #BBAI #USAR #TLRY #ONDS #IRBT #CLSK - More: crystalequityresearch.com/most-searche... - #smallcap

Leading Indicators, Tuesday September 23, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Tue Sept 23rd - #VERU #UPXI #TEAD #SATL #REAX #QURE #PRAA #OFS #MAXN #LIDR #GLTO #FIP #ENTA #DNUT #CLYM #WGO #TFIN #SKIL #NIC #LANV #EVH #CCS #BHE - More: crystalequityresearch.com/leading-indi... - #smallcap

Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates Climb Bio (Nasdaq: CLYM) reported Q2 2025 financial results and provided significant pipeline updates. The company has advanced its two key programs: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL antibody.Key developments include: First patients dosed in both ITP and SLE trials for budoprutug, upcoming initiation of pMN Phase 2 trial, development of a subcutaneous formulation with promising non-clinical data, and advancement of CLYM116 toward clinical development for IgAN. The company appointed Edgar D. Charles, M.D. as Chief Medical Officer.Financial highlights: $187.4 million in cash and equivalents as of June 30, 2025, with runway through 2027. R&D expenses increased to $6.6 million from $1.0 million year-over-year, while G&A expenses were $4.1 million.

#CLYM Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/CLYM/climb-bio-repo...

Clym - Mit Games zum Erfolg - Mit Patrick de Rijk - Nerdwelten Podcast Patrick De Rijk, Protagonist der ARD-Doku „Mit Games zum Erfolg“, spricht mit Hardy und Ben über seinen Weg in die Games-Branche.

Wie wird man mit Games erfolgreich? Wir sprechen mit Patrick, dem Protagonisten der SWR-Doku „Clym – Mit Games zum Erfolg“!

nerdweltenpodcast.com/2025/06/10/c...

👉 #ARDMediathek | #GamingKarriere #Clym #NerdweltenPodcast #Gamesbranche #RetroGaming #PodcastTipps

Climb Bio Launches 3 Major Clinical Trials in 2025 with $198M War Chest for Immune Disease Pipeline Climb Bio advances budoprutug trials for ITP, SLE, and pMN diseases. New CLYM116 drug development on track. $198M cash runway extends through 2027. See trial timeline.

#CLYM Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/CLYM/climb-bio-repo...

Exec Edge Research Launches Initiation Notes on Key Companies Exec Edge is venturing into the research domain with detailed insights on companies like FLD, CLYM, STKS, REX, and ACB, aiding investors.

Exec Edge Research Launches Initiation Notes on Key Companies #USA #Palm_Beach #Exec_Edge #FLD #CLYM

Climb Bio Secures 3-Year Cash Runway with $212M, Advances Multi-Disease Pipeline Just released: Climb Bio strengthens position with $212.5M cash runway and FDA clearances for three immune disease indications. Pipeline expands with CLYM116 acquisition.

#CLYM Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates

www.stocktitan.net/news/CLYM/climb-bio-repo...

Es ist soweit!
Die erste Folge der zweiten Staffel Bau die Burg ist online!
Es geht auf eine der schönsten Burgen überhaupt: Burg Eltz.

youtu.be/MM0Oex8997I?...

#nerdstar
#baudieburg
#dagilp_lbh
#lunarie
#burgeltz
#clym

Climb Bio Secures Novel IgA Nephropathy Treatment in Global Licensing Deal with Beijing Mabworks Climb Bio acquires exclusive rights to CLYM116, a promising anti-APRIL antibody for IgA nephropathy treatment, with $212.9M cash position supporting development through 2027.

#CLYM Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy

www.stocktitan.net/news/CLYM/climb-bio-expa...

Climb Bio to Join NASDAQ Biotechnology Index in Key December Addition Climb Bio (CLYM) achieves significant milestone with upcoming inclusion in the prestigious NASDAQ Biotechnology Index, marking enhanced visibility for institutional investors.

#CLYM Climb Bio to be Added to the Nasdaq Biotechnology Index

www.stocktitan.net/news/CLYM/climb-bio-to-b...

NEWS: ( NASDAQ: #CLYM ) Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

#StockMarket #News